Kyverna Therapeutics, Inc. (KYTX)
5.15
-0.01
(-0.19%)
USD |
NASDAQ |
Nov 04, 16:00
5.12
-0.03
(-0.58%)
After-Hours: 20:00
Kyverna Therapeutics Net Income (Quarterly) : -38.32M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -38.32M |
| March 31, 2026 | -39.73M |
| December 31, 2025 | -37.80M |
| September 30, 2025 | -36.79M |
| June 30, 2025 | -42.08M |
| March 31, 2025 | -44.64M |
| December 31, 2024 | -37.49M |
| September 30, 2024 | -34.49M |
| Date | Value |
|---|---|
| June 30, 2024 | -28.80M |
| March 31, 2024 | -26.69M |
| December 31, 2023 | -20.67M |
| September 30, 2023 | -15.46M |
| June 30, 2023 | -13.09M |
| March 31, 2023 | -11.14M |
| December 31, 2022 | -8.496M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 38.32M |
| EPS Diluted (Quarterly) | -0.6292 |
| Enterprise Value | 151.27M |
| Earnings Yield | -57.00% |
| Normalized Earnings Yield | -57.00 |